Overview
TMAB Therapeutics (TMAB) is on a mission to develop and manufacture potentially best-in-class
radiopharmaceuticals targeting advanced neuroendocrine tumors. Our DLL3-targeting theranostic pair, invented at Memorial Sloan Kettering Cancer Center, is gearing up for a Phase 1 trial.
TMAB is led by Co-Founder and CEO Dr. Tinashe Chandauka, MD/PhD, Oxford Rhodes Scholar and Termeer Fellow.